|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||312.00 - 316.00|
|52-week range||299.01 - 430.00|
|Beta (5Y monthly)||0.21|
|PE ratio (TTM)||16.23|
|Forward dividend & yield||9.97 (3.16%)|
|Ex-dividend date||17 Mar 2022|
|1y target est||423.65|
Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.
SOUTH SAN FRANCISCO, Calif., January 19, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study is evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence. The Tec
UnitedHealth Group, The Coca-Cola, Roche Holding, Lam Research and Valero Energy are part of the Zacks top analyst blog.